| Josephson F, Allqvist A, Janabi M, et al.
CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir. [JOURNAL ARTICLE]
Clin Pharmacol Ther 2007 Feb 28.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Robertson SM, Formentini E, Alfaro RM, et al.
Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort. [Journal Article]
Br J Clin Pharmacol 2006 Apr; 61(4):379-88.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Portilla J, Boix V, Garcia-Henarejos JA, et al.
Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy. [Journal Article, Multicenter Study, Randomized Controlled Trial]
Int J STD AIDS 2005 Dec; 16(12):807-10.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ribera E, Azuaje C, Lopez RM, et al.
Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). [Clinical Trial, Journal Article, Multicenter Study]
J Acquir Immune Defic Syndr 2005 Nov 1; 40(3):317-23.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Smith CJ, Phillips AN, Hill T, et al.
The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. [Journal Article, Multicenter Study]
J Infect Dis 2005 Oct 15; 192(8):1387-97.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Moyle GJ
Saquinavir-soft gel: establishing saquinavir in HAART regimens. [Journal Article]
Expert Opin Investig Drugs 1998 Aug; 7(8):1313-22.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Cardiello P, Srasuebkul P, Hassink E, et al.
The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. [Clinical Trial, Journal Article]
HIV Med 2005 Mar; 6(2):122-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ribera E, Lopez RM, Diaz M, et al.
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. [Clinical Trial, Journal Article]
Antimicrob Agents Chemother 2004 Nov; 48(11):4256-62.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Lamotte C, Landman R, Peytavin G, et al.
Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). [Clinical Trial, Journal Article]
Antivir Ther 2004 Apr; 9(2):247-56.
Abstract | Full Citation | Find Related Articles | | Stephan C, Hentig N, Kourbeti I, et al.
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. [Journal Article]
AIDS 2004 Feb 20; 18(3):503-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
